Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.19.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Revenue:    
Grant and licensing revenue $ 5,793,849 $ 1,519,943
Operating expenses:    
Research and development 16,233,014 8,267,549
General and administrative 7,025,212 6,370,954
Change in fair value of contingent consideration 495,936 224,289
Total operating expenses 23,754,162 14,862,792
Loss from operations (17,960,313) (13,342,849)
Interest income 265,752 22,167
Other income, net 117,780 101,276
Total non-operating income, net 383,532 123,443
Net loss before income tax benefit (17,576,781) (13,219,406)
Income tax benefit 985,488 809,540
Net loss (16,591,293) (12,409,866)
Net loss - non-controlling interest (857,439) (568,195)
Net loss attributable to Heat Biologics, Inc. $ (15,733,854) $ (11,841,671)
Net loss per share attributable to Heat Biologics, Inc.- basic and diluted $ (0.9) $ (3.08)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted 17,485,461 3,845,342
Other comprehensive loss:    
Net loss $ (16,591,293) $ (12,409,866)
Unrealized gain (loss) on foreign currency translation 146,121 (93,794)
Total comprehensive loss (16,445,172) (12,503,660)
Comprehensive loss - non-controlling interest (857,439) (568,195)
Comprehensive loss attributable to Heat Biologics, Inc. $ (15,587,733) $ (11,935,465)